Zanidatamab (Baihe’an®): Un avance clave en el cáncer de vías biliares HER2 positivo

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Zanidatamab #BaiheAn #HER2 #BiliaryTractCancer #Oncology #BispecificAntibody #TargetedTherapy #BreakthroughTherapy #CSCO #CDE #FDA